Systematic review of Purtscher's and Purtscher-like retinopathies

Abstract

Purpose (1) To describe the clinical characteristics of Purtscher and Purtscher-like retinopathies, including etiologies, fundoscopic signs, results of complementary investigation, treatments, and outcomes.

(2) To compare visual acuity (VA) of patients receiving corticosteroids for PuR compared with observation.

Methods Systematic review of several databases (1980–2010): Medline, EMBASE, ISI, EBSCO, Science Direct and Google Scholar. Study selection criteria included: (A) Studies of PuR with ophthalmology assessments; (B) ≥ 3 of 5 diagnostic criteria of PuR; (C) Quantified VA at presentation. For quantitative assessment (purpose 2), we selected only studies that reported whether corticosteroids were administered, and with vision assessments after at least 1 month.

Results (1) From 670 studies initially found, 40 were included (68 cases, 110 eyes): 1 prospective, 5 case series, and 34 case reports. Mean VA at presentation was 1.3 logMAR (logarithm of the minimum angle of resolution) ($< 20/200$; range: 20/20–light perception). Purtscher flecken were underreported. Trauma and acute pancreatitis were the most frequent etiologies. There were six deaths, all with systemic associations. (2) There was no statistically significant difference between VA improvement for patients treated with corticosteroids compared with observation. Visual prognostic factors identified included etiology (pancreatitis and trauma were associated with higher probability of visual improvement) and male gender.

Conclusion Due to limitations of case reports and series, the presented data are only useful as broad characterizations of the clinical course of PuR. Further studies, possibly including trials to assess the effectiveness of corticosteroids use, and larger prospective cohort studies, are

AIM Miguel^{1,2}, F Henriques¹, LFR Azevedo²,
AJR Loureiro¹ and DAL Maberley³

necessary, but may not be feasible to conduct.

Eye (2013) 27, 1–13; doi:10.1038/eye.2012.222;
published online 23 November 2012

Keywords: corticosteroids; Purtscher's retinopathy; Purtscher-like retinopathy; systematic review

Introduction

Purtscher's retinopathy is an occlusive microvasculopathy associated with trauma. It was first described in 1910 by Otmar Purtscher¹ in a middle-aged man who fell off a tree and suffered cranial trauma. There is some doubt about the incidence of this pathology; authors have estimated its incidence at 0.24 persons per million per year (including Purtscher and Purtscher-like retinopathies)² while others believe that the incidence is higher because the condition may frequently be asymptomatic.³ Bilaterality is present in up to 60% of cases.

Purtscher's retinopathy generally occurs as a result of cranial trauma or thoracic compression. When there is a non-traumatic etiology, the correct designation is Purtscher-like retinopathy. Frequent causes of Purtscher-like retinopathy include acute pancreatitis, renal failure, and autoimmune disease. Purtscher-like retinopathy in acute pancreatitis is an indicator of multiorgan failure and is often associated with a fatal outcome.³

The diagnosis of Purtscher's and Purtscher-like retinopathies (PuR) is clinical, with a presentation that usually includes sudden vision loss of variable severity, hours to days after the causal pathology. Fundoscopic signs include cotton-wool spots and intraretinal hemorrhages, described in 83–92% of a series of cases.⁴ Purtscher flecken are considered to be pathognomonic,⁴ but occur in only 50% of cases.

¹Ophthalmology Department, Central University Hospital of Coimbra, Coimbra, Portugal

²Department of Health Information and Decision Sciences, Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal

³Retinal Division, Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence: AIM Miguel, Rua Quinta do Sardoal, VE 3, n°10, 4430-182 Vila Nova de Gaia, Portugal.
Tel: +351 932482477.
E-mail: myworld_ana@hotmail.com

Received: 7 March 2012
Accepted in revised form: 2 October 2012
Published online: 23 November 2012

It is widely assumed that the flecken are the result of occlusion of the precapillary arterioles. The characteristic finding is intraretinal whitening but with a clear zone (within 50 μm) on either side of the retinal arterioles, venules, and precapillary arterioles. This is in contrast to cotton-wool spots, which have ill-defined edges,^{4,5} and are located superficially over vessels. Fluorescein angiography may show leakage of dye from retinal arterioles, capillaries, and venules in patients with relatively mild Purtscher's retinopathy. Arteriolar obstruction is noted in more severe cases. There are many theories about pathogenesis but typically Purtscher's microangiopathy is thought to be due to precapillary occlusion, due to fat emboli, leukoaggregation, or other mechanisms.

Treatment is variable with some physicians observing expectantly and others primarily administering corticosteroids. There have been non-systematic reviews of Purtscher's retinopathy;^{6,7} however, no recent systematic review has been performed. There is a need for an updated systematic review of Purtscher's retinopathy given ongoing controversies regarding treatment, and due to further published cases since prior reviews.

We present a systematic review of Purtscher's retinopathy and Purtscher-like retinopathies. Part one of this review will describe the clinical characteristics of PuR, namely: clinical presentation, causal/associated pathologies, results of diagnostic testing, treatments performed, and clinical outcomes.

In part two of this review, our goal is to assess visual acuity (VA) changes of patients receiving corticosteroids compared with those without treatment (main outcome). Secondary comparisons between groups include an assessment of clinical changes and prognostic factors.

Materials and methods

Search methods

The search methodology was guided by the Cochrane Collaboration's recommendations.⁸ Two independent reviewers, AM and FH, examined each title and abstract to exclude obviously irrelevant reports. They then independently examined the full text of each article to determine eligibility according to the noted selection criteria below. Disagreements were solved by consensus and registered to allow assessment of reliability using the kappa statistics.

Electronic searches included the following databases: Medline (via Pubmed)—1950 to May 2010, EMBASE—1974 to May 2010; ISI—2000 to May 2010, and other databases via EBSCO, Science Direct, and Google Scholar. We also searched clinicaltrials.gov and Current

Controlled Trials (in www.controlled-trials.com).

The search query for Pubmed was '(Purtscher[tiab] OR Purtscher-like[tiab] OR angiopat*[tiab]) AND retinopath*[tiab]'; similar searches were adjusted to each database. All searches were made from 1 to 4 May 2010. No publication date or language exclusions were made. We also hand-searched reference books, journals, and bibliographies from relevant papers. We mailed (or sent letters) to experts in the field for help in identifying the unpublished data and gray literature to avoid publication bias.

Selection criteria

Inclusion criteria were

- Case reports, case series or trials meeting predetermined quality criteria, based on the Cochrane Collaboration,⁸ STARD,⁹ and STROBE.¹⁰
- Patients that matched at least three of five diagnostic PuR criteria (adapted from several papers^{4,7,8}):
 1. Purtscher flecken
 2. Retinal hemorrhages, low-to-moderate number (1–10)
 3. Cotton-wool spots (typically restricted to posterior pole)
 4. Probable or plausible explanatory etiology
 5. Complementary investigation compatible with diagnosis
- Quantified VA at presentation.
- Follow-up by an ophthalmologist with fundoscopic evaluation, at least one month after initial diagnosis.

For the assessment of corticosteroid efficacy in PuR, we only included studies that fulfilled another two inclusion criteria: studies with follow-up at 1 month (with all assessments and VAs registered), and studies reporting whether corticosteroids were administered (if studies did not explicitly note corticosteroids use for each patient, then they were excluded).

Exclusion criteria included: duplicate reports, studies without follow-up, and studies without examinations performed by an ophthalmologist. To avoid language bias, publication language was not an exclusion criteria.

Data collection and analysis

Two reviewers, AM and FH, independently collected data and assessed quality. A form was developed specifically for this project to assist in consistent data collection from each study. This form included: year of publication, author's name, as well as each subject's age, gender, retinal pathology, etiology of retinopathy, and laterality, VA at presentation (VA_0); VA at 1 month (VA_1);

VA at 2 months(VA₂); VA at 6 months(VA₆), diagnostic criteria of PuR, signs and results of tests, and treatment (including dosing and administration route). The investigators had clear coding instructions.

If VA was not recorded in the logarithm of the minimum angle of resolution (logMAR) scale,¹¹ then it was converted. Snellen VA scores were converted to the logMAR for statistical analyses, using the calculation: logMAR value = log₁₀ (1/Snellen). VA scores below Snellen 20/400 were assigned as counting fingers (logMAR value of 1.7), hand motion (logMAR value of 2.5), and light perception (logMAR value of 3.0). Where necessary, authors were contacted by E-mail^{4,12–32} or letter^{1,32} to provide further data (some responses were received^{12,14,17}). Some studies required translation.^{15,20,33–40}

Quality evaluation graphs were made using Review Manager v5 (Cochrane Collaboration, Oxford, UK). Data were collected as part of the quality evaluation process: description of the study design, description of patient demographics, diagnostic criteria used to define PuR, VA testing method, description of results, follow-up examinations made by an ophthalmologist, and follow-up duration.

Quantitative data synthesis

All analyses were performed using Excel for simple calculations or SPSS (SPSS Inc., version 17.0, Chicago, IL, USA). Disagreements regarding study inclusion were calculated using kappa statistics.

Subgroup analyses previously planned were performed: corticosteroid use *vs* no use; presence/absence of associated pathology.

We tried to identify prognostic factors associated with VA improvement, using Fisher's exact test for categorical variables, including: etiology of PuR, gender, bilaterality, presence or absence of Purtscher flecken, presence or absence of retinal edema, and results of complementary tests. Results and features of complementary tests searched included: (1) fluorescein angiography (non-perfusion, early hypofluorescence, delayed filling, peripapillary staining, generalized ischemia, and abnormalities present after 1 month); (2) OCT (retinal edema, atrophy after 1 month); (3) visual field (*scotoma*, visual field alterations after 1 month); (4) visual evoked potentials changes; and (5) Electroretinogram changes.

Univariate analyses of normally distributed continuous variables were performed using Student's *t*-test. Independent samples Mann–Whitney test was used for continuous variables without normal distribution (all variables were tested for normality using Kolmogorov–Smirnov test). Since there were cases of bilateral Purtscher, we ran three separate analyses:

analysis of each involved eye ('all-eyes'), comparison of eyes with best VA ('best-eye'), and worst VA ('worst-eye'). Best eye and worst eye analyses included cases of unilateral PuR. Significance was accepted at 0.05.

Results

The Pubmed search yielded 232 studies; EMBASE yielded 169 results; ISI 89, EBSCO 90 and Google Scholar and hand searching yielded 90 articles. Of the total 670 articles, 65 studies were selected for a full-text review (Figure 1). For study inclusion, kappa was 0.88 (good agreement). In all, 40 studies that included 68 cases (involving 110 eyes) were included for our descriptive review; and 23 studies (with 24 cases and 35 eyes) were included for the quantification of VA improvement and response to corticosteroid therapy.

Demographic details

Characteristics of included studies. The characteristics of the 40 included studies are summarized in Table 1. Most studies were case reports, although some were case series and one was a prospective study.²

Characteristics of patients. The mean patient age was 34 years (minimum 11 weeks and maximum 76 years) and 60% were male. The mean time of follow-up was 20.3 months (with a minimum of 30 days and maximum of 96 months).

Figure 1 Flowchart of search strategy.

Table 1 Characteristics of included studies

Author ^a	Age, sex, etiology Presentation time (1 st if 1 st symptom of associated pathology) Follow-up time (m = months)	Laterality; visual acuity (VA ₀ = at presentation; VA ₁ = at 1 month; VA ₂ = at 2 months; VA ₆ = at 6 months)	Signs at presentation (and other signs) ^a	Exams N = none R = not reported	Corticoids Y = yes N = no R = not reported
Alasil ⁵³	31y; M; acute pancreatitis(AP) 'Recent'; 6m	OD VA ₀ : 20/100; VA ₆ : 20/30	PP ⁺ , ME, relative afferent papillary defect	IVFA ₀ : OD: areas non-perfusion and late leakage; OS: less dramatic. OCT ₀ : OD: RNFL swelling and subretinal fluid; OS: retinal thickening supranasally; OCT ₆ : normal	N
Miguel ⁵⁴	31y; M; car accident (leading to PR in OD and traumatic optic neuropathy in OS) 12 h; 7m	OD VA ₀ : MP 50 cm VA _{1m} : CF 1 meter VA _{2m} & 6m & 7m: CF 2 meters	PP ⁺ ; RH; CS; PCR 1 month: OD normalization; OS partial optic atrophy 6 months: OD normal; OS total optic atrophy	IVFA ₀ : generalized defect OD, nasal step OS; VF ₀ : slightly worse ODS VF ₆ : hypofluorescence in the areas of hemorrhage, late leakage inframacular and peripapillary OD; peripapillary staining in OS OCT ₀ : unmarked retinal edema; OCT _{1m} : retinal atrophy with loss of foveal architecture OD; normal in OE VEP _{0&6m} : OS with big latency and small amplitude and wave P100 unnoticeable IVFA ₆ : severe ischemia of the nasal macular retinal arterioles with extensive secondary late leakage	Y (Prednisone <i>per os</i> 60 mg/ day 4 weeks, then tapering)
Nautiyal ⁴⁷	53y; M; multiple myeloma; 1 st ; 8m	ODS VA ₀ : 20/100 VA ₆ : 20/400; 20/30	PP ⁺ , RH, CS DS	PE, RH, CS DS	Y ('high dose')
Tajunisah ⁵⁵	20y; F; thrombotic thrombocytopenic purpura (TTP) days; 3w († died)	ODS VA ₀ : counting fingers ODS Case 1: ODS; VA ₀ : good light fixation (G); VA _{3y} : 20/20; 20/50	PP ⁺ , RH, CS	R	Y
Sturm ⁵⁶	All cases of hemolytic uremic syndrome *Case 1: 1; F; NA; 3y *Case 2: 1; F; ODS; NA; 6y *Case 3: 3; F; NA; 6w	Case 2: ODS; VA ₀ : G; VA _{6y} : 20/ 60; 20/100 Case 3: ODS; VA ₀ : 20/20; VA _{6w} : 20/20	PP ⁺ , case 2 RH: cases 1–3 CS: cases 1, 2	R	Case 2: N Cases 1, 3: R
Pina ⁴	57, M, renal scleroderma; days, months (does not specify)	ODE; VA ₀ : 6/10; 3/10; VA _{3w} : 7/10; 5/ 10	RH, CS	IVFA: late choroidal perfusion of posterior pole and visualization of 'big' choroidal vessels and early venous perfusion; non-perfusion of capillary bed of retina in the region of cotton-wool spots IVFA compatible	Y (solumedrol bolus, and then 4 days of corticosteroids <i>per os</i> (dosing?) N
Krahulec ¹⁴	27; F; AP 2d; 1m	ODS VA ₀ : 1/10; 1/20; VA _{2w} : 20/32; 10/20; VA _{1m} : 20/ 25; 20/32	PE, RH, CS DS, ME	OCT ₀ : retinal edema; 2w & 1m: normal	N
Sauer ¹⁵	47y; M; cryoglobulinemia in C hepatitis; weeks; 6m	ODS VA ₀ : 20/50; 20/25 VA ₆ : 20/20 ODS	RH, CS	IVFA: 'diffusion of coloring agent from arterioles, capillaries and venules in the aerie of white retinal lesions' OCT: slight edema of the neuroepithelium OD ERG: 'A-waves and B-waves were depressed suggesting damage to both outer and inner retinal layers'	N
Holak ¹⁸	Case 1: 26y; M; AP; days; 5y Case 2: 61y; M; hepatitis C with cryoglobulinemia; OS; 1 st ; 3y †died (cryo.) Case 3: 23y; F; sepsis postcesarean ODS; 2m; 8y Case 4: 38y; M; AP; ODS; 1 st ; 2w (patient left consultations) Case 5: 29y; F; motorcycle accident OD; 4d; 2m	1: ODS VA ₀ : 0.1; 0.06 VA _{1w} : 0.6; 0.2 2: OS VA ₀ : 1; 1/35; VA _{10d} : 1; 0.1; VA _{4m} : 1; 0.4 3: ODS VA ₀ : 1/50; 1/25 VA _{3w} : 0.06; 0.08; VA _{8y} : 0.06; 0.08 4: ODS VA ₀ : 0.4; 0.5; VA _{2w} : 0.8; 0.9 5: OD VA ₀ : 0.2; 1; VA _{2m} : 0.9; 1 1: VA ₀ : CF ODS; VA ₆ : CF ODS 2: VA ₀ : CF ODS; VA ₆ : 6/60; CF 3: VA ₀ : 6/18; HM; VA ₆ : 6/6; CF 4: VA ₀ : 6/5; 6/6; VA ₆ : 6/5 ODS 5: VA ₀ : 6/60; 2/60; VA ₆ : 6/6 ODS 6: VA ₀ : 6/12 ODS; VA ₆ : 6/6 ODS 7: VA ₀ : HM/6/5; VA ₆ : HM, 6/6 8: VA ₀ : HM OD; VA ₆ : 6/6 OD 9: VA ₀ : 6/60 OD; VA ₆ : 6/60 OD	PP ⁺ : 1, 2, 4, 5 RH: 1–3, 5 CS: 1–5 ME: 1–5 PCR: 1 Case 1 _{7month} : atrophy optic nerve, mottling EPR; Case 2 _{4m} : atrophy optic nerve; Case 3 _{6m} : atrophy optic nerve; mottling EPR; Case 5 _{2m} : normal	1: Y (100 mg prednisone iv 1w) 2: Y (100 mg prednisone iv) 3: Y (50 mg iv prednisone 3 days; 100 mg <i>per os</i> 2w) 4: Y (100 mg prednisone iv 2w) 5: Y (100 mg prednisone id <i>per</i> <i>os</i> 2w)	
Agrawal ²	All cases: presentation time not reported; follow-up 6m etiologies: PA: 1–3; chest compression: 4–9; road traffic accident + long bone fracture: 10–13; road traffic accident: 14, 15 Cases: 1: 36; F; ODS; R; 6m 2: 38; F; AP; ODS 3: 31; M; ODS 4: 30; M; ODS 5: 50; M; ODS	1: VA ₀ : 6/5; 6/6; VA ₆ : 6/5 ODS 2: VA ₀ : 6/60; 2/60; VA ₆ : 6/6 ODS 3: 31; M; ODS 4: 30; M; ODS 5: 50; M; ODS	PF: 1–3, 7–9, 12–13 CS: 1–3, 5–15	R	R (some patients received steroids, but does not specify who)

Table (Continued)

Author ^{ref}	Age, sex, etiology Presentation time (1 st if 1 st symptom of associated pathology) Follow-up time (n = months)	Laterality; visual acuity (VA ₀ = at presentation; VA ₁ = at 1 month; VA ₂ = at 2 months; VA ₆ = at 6 months)	Signs at presentation (and other signs) ^a	Exams N = none R = not reported	Corticoids Y = yes N = no R = not reported
	6: 48; M; ODS 7: 37; M; ODS 8: 76; F; OD 9: 25; M; OD 10: 67; F; ODS 11: 38; M; OD 12: 44; F; OD 13: 44; M; OD 14: 32; M; ODS 15: 37; M; OS 27; M; adult onset Still's disease with TTP 1m; 1m (left consultations)	10: VA ₀ : 6/9 ODS; VA ₆ : 6/9; 6/6 11: VA ₀ : 6/36 OD; VA ₆ : 6/18 OD 12: VA ₀ : 6/180 OD; VA ₆ : 6/5 OD 13: VA ₀ : 6/9 OD; VA ₆ : 6/9 OD 14: VA ₀ : HM ODS; VA ₆ : 6/5 ODS 15: VA ₀ : HM OS; VA ₆ : 6/60 OS			
Okwuosa ¹⁷		ODS VA ₀ : 20/40; 20/300 VA _{1m} : 20/50; 20/400	CS ME	IVFA ₀ : precapillary occlusion; hypofluorescence in locals of cotton- wool spots, and pinpoint areas of early hyperfluorescence that leaked in the late phase OCT ₀ : central macular thickness of 308 microns in the right eye and 646 microns in the left eye with subretinal serous fluid; OCT _{1m} : 253 microns OD; 355 microns OS R	Y (prednisone, dosing not reported)
Parc ¹⁹	31y; F; thrombotic microangiopathy after antineoplastic therapy for Hodgkin's lymphoma; hours; R	ODS VA ₀ : 20/400 ODS; VA _{follow-up} : R	PP ₀ , RH, CS DS, PCR	N	N
Stewart ¹⁶	25y; F; HELLP syndrome in pregnancy; 1 st ; 7m	ODS VA: CF 2 feet; VA _{7m} after birth: CF 2 feet	PP ₀ , RH, CS DS, PCR		Y (methylprednisolone 1 g/ day iv)
Holak ²⁰	1: 29y; M; traffic accident with chest compression; hours; 2m 2: 23y; F; gestosis; days, 8y	1: OD; VA ₀ : 0.1; 1; VA _{1m} : 0.7; 1; VA _{2m} : 1; 1 2: ODS; VA ₀ : 1/50; 1/25; VA _{6m} : 0.06; 0.08; VA _{8y} : 0.06; 0.08	PF: 1; RH: 1, 2; CS: 1, 2 1: preretinal hemorrhage; 2m: normalization 2.6m: partial optic atrophy	Case 1: IVFA1: 'peripapillary hypofluorescence in the affected retinal areas'; IVFA _{1m} : regression of hypofluorescence, light hyperfluorescence perimacular'; IVFA _{2m} : 'normalization' OCT ₀ : 1: 'peripapillary and retinal thickening; fovea with 320 microns; average retina with 400 microns'; OCT _{1m} : 'decrease in the retinal thickness; fovea with 210 microns'; OCT _{2m} : normal; 2: OCT _{8y} : '<100 microns' 1: ERG _{2m} : normal; 2 _{8y} : 'reduced amplitudes: OD 16 microvolts, OS 22 microvolts' IVFA ₀ : 'areas without capillary perfusion corresponding to the presence of exudate followed by belated diffusion and screening effect caused by retinal hemorrhage' IVFA: ischemia due to the retinal artery obstruction; leakage from vessels in the areas corresponding to the CS OCT ₀ : retinal edema; OCT ₆ : normal IVFA ₀ : 'decreased capillary perfusion of the right macular area' VF Goldmann ₀ : central scotoma OD; VFGoldmann _{2m} : central scotoma OD IVFA ₀ : 'multiple pinpoint areas of hyperfluorescence at the level of the EPR that leaked in the later frames'; IVFA _{5m} : normal	Y (both 100 mg prednisone per os id 2w)
López-Tizón ²¹	36; M; AP; hours; 2m	ODS VA ₀ : HM ODS; VA _{2m} : 1	PP ₀ , RH, CS DS, ME		
Carrera ⁴³	35y; M; Acute alcoholic pancreatitis; hours; 2m	ODS VA ₀ : CF ODS; VA _{2m} : 20/20; 20/100	PP ₀ , RH, CS 7m: normalization		
Nayak ²²	50; M; motorcycle accident with long bone fracture; 2d; 2m	OD: VA ₀ : 6/12; 6/6; VA _{2m} : 6/9; 6/6	RH, CS; PCR 7m: severe optic atrophy and retinal thinning		
Lai ²³	26; M; acute allograft renal rejection; 1d; 5m	ODS VA ₀ : 20/400 ODS; VA _{3m} : 20/70; 20/20	PP ₀ , CS PCR 5m: 'OD; macular pigmentary mottling' PP ₀ , RH, CS, ME		
Ong ²⁴	34; F; PTT; 2d; follow-up: > 1m but not specified	ODS VA ₀ : 6/24; 6/60	PP ₀ , RH, CS		Y (methylprednisolone 1 g/d iv)
Fumex ³²	31; F; AP; 3d; 2m	ODS VA ₀ : 1/20 ODS VA _{1m} : 8/10; 1/10 VA _{2m} : 8/10; 1/10			N
Castillo ²⁵	29; F; coil embolization and balloon occlusion of an intracavernous carotid aneurysm; 1d; 1m	OD VA ₀ : 20/20 VA _{1m} : 20/20	CS PCR Also: mild ptosis 2.5 mm and miosis 3 mm OD (Horner's syndrome) which remained at 1m	VF automated ₀ 'normal' VF automated _{1m} : 'normal'	N
Kocak ²⁶	17; M; weight-lifting; 2w; 3m	OS VA ₀ : 20/200; VA _{3m} : 20/20	RH, CS DS Signs _{3m} : normalization	IVFA ₀ : 'scattered hypofluorescent areas in the posterior pole, partial occlusion in the inferior and inferotemporal branch retinal veins in	N

Table (Continued)

Author ^{ref}	Age, sex, etiology Presentation time (1 st if 1 st symptom of associated pathology) Follow-up time (m = months)	Laterality, visual acuity (VA ₀ = at presentation; VA ₁ = at 1 month; VA ₂ = at 2 months; VA ₆ = at 6 months)	Signs at presentation (and other signs) ^a	Exams N = none R = not reported	Corticoids Y = yes N = no R = not reported
Haq ²⁸	19; M; acute pancreatitis; 1 st ; 6m	ODS VA _{0&1m} : CF 4 feet ODS; VA _{6m} : CF 4 feet; 20/40	PP ^a , RH ^a , CS PCR	the midphase and complete filling in the late phase' Indocyanine green ^q : 'hypocyanescent areas' Multifocal ERG _{1w} : 'significantly decreased responses in A&B waves; mERG _{1m} : similar; mERG _{6m} : 'increase in the ratio of amplitude responses [...] slightly higher in the left eye' IVFA ₀ : '1 bilateral macula ischemia'; IVFA _{6m} : 'changing of the anastomotic perivascular arch'; IVFA ₂₀ : 'ischemia of posterior pole VF; central scotomata ODS; VF _{6m} : central scotoma ODS IVFA ₀ : 'zones of capillary obstruction and non-perfusion of retina VF _{3m} : central scotoma ODS	N
Sellami ⁴⁴	1: 27; F; Lupus; 1 st ; 6m 2: 30; F; lupus; hours; days († of hepatic and renal insufficiency by lupus) 27; M; AP; 3d; 3m	1: ODS; VA _{0&6m} : 1/20 ODS 2: VA ₀ : 1/20 OS	PP ^a ; 1; RH 1, 2; CS: 1, 2 DS1 ^a ; ME1; PCR1 1 at 6m: normalization PP ^a , RH, CS ME, PCR		1: Y (solumedrol bolus, dose R); 2: R
Bécheur ⁵⁷		ODS VA ₀ : 1/10 ODS; VA _{3m} : 1/20; 1/10	PF, RH, CS PCR ^a Fundoscopy _{2w} : massive, confluent peripapillary and macular whitening DS, PCR DS, PCR Signs _{6m} : optic atrophy PF, RH, CS DS Signs _{2w} : normal except for narrowing and sheathing of retinal arterioles PP ^a , RH, CS PCR		R
Bui ⁵⁸	32; M; ODS; drug-induced PA in HIV +, that worsened at 2w; 1w; 1m (then lost to follow-up)	ODS VA ₀ : 20/25; CF 3 feet; VA _{2w} : HM ODS; VA _{1m} : 20/20; 20/80	PF, RH, CS PCR ^a Fundoscopy _{2w} : massive, confluent peripapillary and macular whitening DS, PCR DS, PCR Signs _{6m} : optic atrophy PF, RH, CS DS Signs _{2w} : normal except for narrowing and sheathing of retinal arterioles PP ^a , RH, CS PCR		N
Patel ⁵⁹	52; F; PTT; 1 st ; 10d († of PTT)	ODS VA ₀ : CF 2 feet ODS	PF, RH, CS PCR ^a Fundoscopy _{2w} : massive, confluent peripapillary and macular whitening DS, PCR DS, PCR Signs _{6m} : optic atrophy PF, RH, CS DS Signs _{2w} : normal except for narrowing and sheathing of retinal arterioles PP ^a , RH, CS PCR		N
Myers ³⁰	41; M; cryoglobulinemia with hepatitis C; 1 st ; 6m	ODS VA ₀ : 20/20; 1/200; VA _{6w & 6m} : 20/20; 20/200 Unilateral but site R VA ₀ : 20/120; VA _{2m} : 20/20 VA _{1y} : 20/20	PF, RH, CS DS, PCR DS, PCR Signs _{6m} : optic atrophy PF, RH, CS DS Signs _{2w} : normal except for narrowing and sheathing of retinal arterioles PP ^a , RH, CS PCR		Y (prednisone <i>per os</i> , dose R)
Lim ²⁹	46; M; retrobulbar anesthesia for pterygium; 1d; 2m	ODS VA ₀ : 20/120; VA _{2m} : 20/20 VA _{1y} : 20/20	PF, RH, CS DS, PCR DS, PCR Signs _{6m} : optic atrophy PF, RH, CS DS Signs _{2w} : normal except for narrowing and sheathing of retinal arterioles PP ^a , RH, CS PCR		Y (prednisone 80 mg/d)
Zwolińska ³¹	4; M; nephrotic syndrome; 1m; 2m	ODS VA ₀ : CF 2.5m; VA _{2d} : 'better' (R) VA _{2m} : 0.9 ODS	PF, RH, CS PCR		Y (methylprednisolone 500 mg/d)
Banach ⁶⁰	59; M; necrotizing vasculitis with Gemcitabine for lung cancer; 10m; 12m († metastatic lung cancer)	ODS VA ₀ : 20/50; CF 5 feet	RH, CS		R
Tabandeh ⁶¹	63; F; pancreatic carcinoma; 1 st ; 3m († carcinoma)	ODS VA ₀ : 20/20 ODS	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		N
Blodi ⁵²	72; M; retrobulbar anesthesia; 1d; 2m	OS VA ₀ : CF OS; VA _{1w} : 20/200; VA _{3w} : 20/80; VA _{2m} : 20/25	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		N
Power ⁶²	29; F; PTT; 1 st ; 6m	ODS VA ₀ : 20/20 ODS	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		N
Atabay ⁶³	25; M; road traffic accident; 1d; 3m	OS VA ₀ : 20/800; VA _{3d} : 20/70; VA _{1w} : 20/50; VA _{1m} : 20/40; VA _{3m} : 20/40	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		N
Schipper ⁶⁴	All cases from valsalva maneuver 1: 29; M; 1d; 6m 2: 28; M; hours; 6m 3: 39; F; 1d; 6m 4: 20; M; 1d; 3m 5: 75; F; 1d; 1m	1: OS; VA ₀ : 20/20; CF; VA _{6m} : 20/20 ODS 2: OS; VA _{0 & 6m} : 20/20 ODS 3: OS; VA _{0 & 6m} : 20/20 ODS 4: OS; VA ₀ : 20/20; CF 1 meter 5: OS; VA ₀ : LP; 0.6; VA _{1m} : LP; 0.6 VA ₀ : 0.5 VA _{1.5y} : 0.5	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		N
Fellinger ³⁷	19; M; car accident with chest compression; days; 1.5y	OS VA ₀ : 0.5 VA _{1.5y} : 0.5	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		R
Teichmann ⁶⁵	1: 25; M; traffic accident with bone fracture; immediate; 4m	1: OD; VA _{0&4m} : 1/50 2: OS; VA _{0&1w&4m} : CF 1 meter	PF, CS Signs: severe optic atrophy and retinal thinning PP ^a , RH, CS Signs _{2m} : normalization without pigmentary changes of EPR PP ^a , RH, CS DS, PCR Signs _{6m} : 'peripapillary EPR disruption and optic atrophy' RH, CS Signs: left afferent papillary defect of 2.2 log units; achromatopsia; Signs _{3d} : marked improvement; Signs _{2m} : optic atrophy PP ^a , RH: 1–4, CSI–4 DS4 Signs 1 & 2 _{em} : 'improvement'; Sign 4 _{em} : temporal optic atrophy; Sign 5 _{em} : optic trophic OD; normalization OS PP ^a , RH, CS ME Signs _{3y} : normalization except for altered macular reflex PP ^a 1, 2; RH1, 2; CSI, 2 ME1, 2; PCR1, 2		R

Table (Continued)

Author ^a	Age, sex, etiology Presentation time (1 st if 1 st symptom of associated pathology) Follow-up time (n = months)	Laterality; visual acuity (VA ₀ = at presentation; VA ₁ = at 1 month; VA ₂ = at 2 months; VA ₆ = at 6 months)	Signs at presentation (and other signs) ^b	Exams N = none R = not reported	Corticoids Y = yes N = no R = not reported
	2: 31; M; work accident (head crushing); immediate; 4m		Sign 1 4m: 'optic atrophy, macular pigmentary changes'	venous phase ^c Case 2: IVFA _{1w} : 'arteriolar closures in early venous phase; late phase with staining of veins, venules & arterioles' VF _{1w} : centronasal defect IVFA ₀ : slow arterial filling, areas of non-perfusion VF ₀ : central scotoma ODS; VF _{3w} & 6m: residual ERG & VEP ₀ : normal	N
Baarsma ⁶⁶	8; M; traffic accident with chest compression; hours; 6m	ODS VA ₀ : 1/60 ODS; VA _{3w} : 0.4; 0.1 VA _{6m} : 0.8 ODS	PP ^a , RH, CS PCR Sign 5m: severe optic atrophy and retinal thinning RH1, 2; CS1, 2 Case 1 _{2m} : normal		N
Tomas ⁶⁷	Cases of battered infants with signs of chest compression 1: 18w; F; ODS; NA; 2m 2: 2; F; ODS; NA; 1y	1: ODS VA ₀ 2m: fix & follow-light (L) 2: ODS VA ₀ : L; VA _{1y} : 'normal'		N	1: N 2: Y (dexamethasone)

Abbreviations: CF, counting fingers; CS, cotton-wool spots; d, days; DS, optic disk swelling; F, female; iv, intravenous; m, months; M, male; ME, macular edema; MP, movement perception; NA, not applicable; OD, right eye; OS, left eye; ODS, both eyes; PCR, pseudo-cherry red spot; PF, Purtscher flecken; R, not reported; RH, retinal hemorrhage; VA, visual acuity; w, weeks; y, years.
 The included studies are represented in this table, as well as clinical characteristics of each case of Purtscher's retinopathy.
 When PuR is bilateral, the first VA value refers to the right eye and the second to the left eye.
^a Not described by respective authors but shown in figures.

Systemic associations of PuR

Table 2 presents the relative frequency of associated pathology in each patient with PuR; the most frequent being trauma, followed by acute pancreatitis. Death occurred in 6 (out of 68 PuR cases) patients, 2 with thrombotic thrombocytopenic purpura (TTP), of 5 cases of TTP. Of those five patients with TTP, only one had unilateral involvement. All cases related to pregnancy and TTP were bilateral. Only one case of acute pancreatitis had unilateral Purtscher-like retinopathy.

Clinical signs of PuR at baseline and follow-up

The most frequently encountered signs of PuR were cotton-wool spots which occurred in 63/68 (93%) of cases, followed by retinal hemorrhages (44/68, 65%), and by Purtscher flecken (43/68, 63%).

Of the 43 cases with Purtscher flecken, 8 were correctly reported (Purtscher flecken were reported and a picture was presented with that sign), 22 cases were not reported by authors but identified during image assessments by reviewers as part of this study, and 13 cases were reported but no photograph was provided. Ten cases presented a picture without Purtscher flecken and correctly did not report it. Fifteen cases had no report of Purtscher flecken and did not present a photograph.

Occasionally, there were other signs at presentation, such as macular edema (22%), optic disk swelling (16%), and a pseudo cherry red spot (26%).

Fundoscopy findings after 2 months follow-up were reported in 22 cases and included: normalization of the retinal appearance (9/22, 40%), optic atrophy (14/22, 64%), mottling of the retinal pigment epithelium (5/22, 23%), retinal thinning (3/22, 14%), and narrowing of retinal arteries (1/22, 4%). Some cases had several signs (the most frequent combination was optic atrophy with mottling of retinal pigment epithelium).

Fluorescein angiography was performed in 31 cases (45.5% of patients and showed: areas of non-perfusion (22/31, 70%), retinal ischemia (22/31, 70%), early hypofluorescence (6/31, 20%), slower filling of vessels (14/31, 45%), late leakage (6/31, 20%), peripapillary staining (5/31, 16%), and precapillary occlusion (2/31, 6.7%).

Ocular coherence tomography (OCT) was performed in eight cases at presentation and showed retinal edema in seven cases and slight thickening in the other case. OCT findings after 1 month were performed in seven cases showing normalization in five cases and macular atrophy in two cases (both with severe macular edema at presentation).

Visual field tests were performed at presentation in 14 cases: 13 showing a central scotoma (93%), of which

Table 2 Etiologies of PuR

Associated pathology	Frequency (number of cases)	Relative frequency (%)	Bilaterality (%)	Reported death	Mean VA at presentation (logMAR)	Mean VA at 6 months (logMAR)
Trauma	23	33.8	12 (52.2%)	0	1.48	0.90
Acute pancreatitis	13	19.1	12 (92.3%)	0	1.51	0.40
Valsalva maneuver	6	8.8	1 (16.6%)	0	0	0
Thrombotic thrombocytopenic purpura	5	7.3	5 (100%)	2 (both with bilateral involvement)	1.43	1.70
Hemolytic uremic syndrome	3	4.4	3	0	0	0.50
Cryoglobulinemia in hepatitis C	3	4.4	3	1 (bilateral involvement)	1.38	0.50
Pregnancy related (HELLP, sepsis post-caesarean and gestosis)	3	4.4	3 (100%)	0	1.90	1.65
Lupus	2	3	1 (50%)	1 (unilateral)	1.70	1.70
Retrobulbar anesthesia	2	3	0 (0%)	0	1.25	0
Pancreatic carcinoma	1	1.5	1	1 (bilateral)	0	NA (0 at 3 months)
Thrombotic microangiopathy after antineoplastic use	1	1.5	1 (100%)	0	1.43	Not reported
Necrotizing vasculitis with lung cancer	1	1.5	1 (100%)	1 (bilateral)	1	Not reported
Acute allograft rejection	1	1.5	1 (100%)	0	1.70	NA (0.30 at 5 months)
Renal sclerodermia	1	1.5	1(100%)	0	0.15	NA (0.20 at 1 month)
Nephrotic syndrome	1	1.5	1 (100%)	0	1.70	NA (0.90 at 2 months)
Multiple myeloma	1	1.5	1 (100%)	0	0.70	0.40
Coil embolization of intracavernous carotid aneurism	1	1.5	0 (0%)	0	0	NA (0 at 1 month)

Abbreviations: VA, visual acuity; NA, not available.

Characteristics of etiologies of Purtscher and Purtscher-like retinopathies are presented.

2 cases had also a nasal step and another had an arcuate scotoma and nasal step. Further visual field testing after 1 month of follow-up was performed in 11 cases, with normalization in 1 case, scotoma enlargement in 1 case, persistent defect in 6 cases, and partial improvement in the remaining 3 cases.

Visual evoked potentials were performed in three cases, showing increased latency and decreased amplitude of responses (two cases) or no alteration (one case); after 1 month, one case improved partially and the other did not. *Electroretinogram* was performed at presentation in two cases, both demonstrating depression of the *a* and *b* waves. Electroretinogram after first month of follow-up was performed in five cases (including the two studied at baseline): one showed normalization, one showed persistent defect; the remaining (not studied at baseline) showed subnormal results.

Risk of bias assessment

We performed a quality evaluation/general risk of bias assessment of all studies; however, we present results of

Figure 2 Risk of bias graph.

only the studies included for quantitative analysis to identify and reduce methodological heterogeneity.

In Figure 2, we present the summary of our quality evaluation of included studies, according to each parameter assessed—risk of bias graph. Most studies had low risk of bias in the description of results but not in the quantification of VA. In fact, there was a high risk of bias in VA quantification (at 1, 2, and 6 months), which adds heterogeneity. Few studies reported strategies to prevent selection bias, information bias, or other bias. Risk of bias

in each study for each of those variables can be requested to the corresponding author.

Quantitative analysis

VA is reported at 1, 2, and 6 months because almost all studies reported those time points. Studies that did not report corticosteroid use or that had a follow-up of <1 month were excluded. Consequently, of 40 studies that were included in the descriptive review (purpose 1), only 24 cases (from 23 studies) were selected for quantitative analysis (purpose 2). From these, 12 cases reported VA at 1 month, 10 cases reported VA at 2 months, and 11 cases reported VA at 6 months (final VA).

VA at presentation and after follow-up. According to our 'best-eye' analysis, mean VA at presentation was 1.5 logMAR (equivalent to <20/200) with standard deviation of 0.75; this value had extreme variability (20/20 to light perception). Our 'worst-eye' analysis showed similar values. In the 'best-eye' analysis, the mean final VA improvement was 0.85 logMAR (equivalent to 0.13 in decimal scale) with standard deviation of 0.82; in 'worst-eye' was 0.96 logMAR (SD = 0.80); in 'all-eyes' was 0.91 logMAR (SD = 0.86).

VA according to associated pathology. VA at presentation according to etiology is represented in Figure 3. Cases

associated with Valsalva and coil-embolization of carotid aneurism²⁵ presented with the best VA (logMAR = 0), while cases of PuR associated with pregnancy or lupus presented the worst (respectively 1.90 and 1.70 logMAR).

The highest VA mean improvement occurred in acute pancreatitis (1.23 logMAR; SD = 1.10) and in trauma (1.35 logMAR; SD = 0.78).

VA improvement in corticosteroid vs no corticosteroid use. There was no statistically significant difference in VA improvement between patients receiving corticosteroids vs no corticosteroids, at 1, 2, or 6 months of follow-up (Fisher's exact test, $P = 0.332$ at 6 months in 'best-eye' analysis; $P = 0.356$ in 'all-eyes'; $P = 1$ in 'worst-eye').

Bilateral Purtscher retinopathy. There was no statistically significant difference between VA or VA improvement of left or right eye, at presentation, at 1 month, at 2 months, or at 6 months of follow-up (2 related samples non-parametric t -test) in the 14 bilateral cases.

Prognostic factors. There were six deaths among all cases. Systemic etiologies with fatal outcomes were cancer (two deaths in two patients), thrombotic thrombocytopenic purpura (two deaths in five patients), cryoglobulinemia (one death in three patients), and

Figure 3 Mean visual acuity at presentation according to etiology. In logMAR scale, 0 is equivalent to normal VA; the higher the value of logMAR, the worse is VA.

lupus (one death in two patients). Death was not associated with initial VA (Mann–Whitney test for initial VA *vs* death). Five of these deaths occurred within 3 weeks of PuR diagnosis.

As for prognostic factors for VA improvement, we identified, in the 'best-eye' analysis *male gender* was associated with better VA improvement at 2 months ($P = 0.018$, Fisher's exact test) and at 6 months ($P = 0.041$, Fisher's test) but not at 1 month ($P = 0.333$). This was similar for the 'worst-eye' analysis ($P_{2\text{ months}} = 0.036$; $P_{6\text{ months}} = 0.038$) and 'all-eyes' ($P_{2\text{ months}} = 0.011$; $P_{6\text{ months}} = 0.004$) analyses.

Etiology of PuR may be associated with VA improvement at 1 month and 2 months, particularly in trauma and acute pancreatitis ('best-eye' with Fisher's test with $P = 0.010$ and $P = 0.002$, respectively) but not with VA improvement at 6 months. Results were similar for 'worst-eye' ($P_{1m} = 0.015$; $P_{2m} = 0.515$; $P_{6m} = 0.612$) and 'all-eyes' ($P_{1m} = 0.001$; $P_{2m} = 0.294$; $P_{6m} = 0.140$) analyses.

According to 'all-eyes' analysis (but neither 'best-eye' nor 'worst-eye'), *absence of macular edema* was associated with higher VA improvement at 2 months ($P = 0.029$; but neither at 1 nor at 6 months); and *absence of pseudo cherry red spot* with better VA improvement at 6 months ($P = 0.017$).

Poor prognostic factors for visual improvement such as choroidal hypoperfusion, optic disc swelling,⁷ or massive Purtscher flecken¹⁸ were not statistically significant, but only a small number of cases presented with these findings.

Discussion

This systematic review provides an up-to-date, comprehensive assessment of the literature regarding Purtscher's retinopathy. Efforts have been made to build a comprehensive, quantitative assessment of the available data, which is of relatively low quality.

Purtscher flecken were reported in 23% but were visible in 63% of the fundus images available in each report (identified by reviewers). The relatively poor identification of Purtscher flecken by authors of included papers suggests that attention should be paid to recognize and document this particular characteristic of PuR, since it is pathognomonic. On the other hand, this particular sign is not of prognostic value.

Visual prognostic factors identified included etiology (pancreatitis and trauma associated with higher probability of visual improvement). Male gender was also a good prognostic factor; however, this may be due to higher preponderance of males in etiologies of good prognostic value (like trauma); we had insufficient power to run a subgroup analysis to clarify this issue.

Unlike other studies that discussed prognostic factors for PuR,¹⁸ we did not find any fundoscopic or angiographic sign of prognostic value for VA improvement.

Only one third of the initial studies presented VA data after follow-up. We would like to emphasize the importance of reporting clinical signs and VA in future studies of PuR not only for the time of presentation but also after follow-up, to better understand the behavior of this pathology over time.

Limitations of this review include the preponderance of clinical cases and series from which our data were derived. In spite of the quality evaluation performed for each study, in case reports there is no unified methodology, which limits the comparability. In the case of VA, not all studies reported vision at consistent time points, as a result, all of these values are considered to be an estimate. On the other hand, in rare pathologies such as PuR in which there are no trials, a systematic review of clinical cases is a valid adapted methodology.

In addition, there may be publication bias and misclassification bias among the included studies. Therefore, the value of our quantitative analysis is limited and should be interpreted with caution. Nonetheless, there certainly appears to be a definite trend toward improved vision within the first 2 months following onset of Purtscher's.

As previously stated, it is agreed that diagnosis of PuR is clinical, being confirmed by angiography. However, the biologic mechanism of injury remains uncertain.

Histopathological studies show signs of retinal vascular occlusion with edema of retinal internal layers, subretinal cystoid space, and abrupt transition to normal retina.^{5,41}

There are several theories that have been forwarded since the initial mechanical theory.¹ The most currently accepted is microembolization, causing arteriolar precapillary occlusion and microvascular infarct of retinal nerve fiber layer, forming cotton-wool spots.^{5,7,16} This could be due to a fat emboli (typically described in long bone fracture⁴²) or due to pancreatic proteases in systemic circulation (typically described in acute pancreatitis^{34,43}).

Leukoembolization by leukocytary aggregation and C5 complement activation with secondary lymph extravasation^{7,44} is another proposed mechanism (also supported by some experimental studies⁴⁵). Other pathogenic processes that may be involved include capillary endothelial damage (supported by late leakage in IVFA¹⁶), sudden increase of intracranial pressure (causing precapillary occlusion in lamina crivosa^{43,46}), sudden expansion of retinal veins,⁷ or hyperviscosity (such as in multiple myeloma⁴⁷). A recent study used computer dynamic flow simulations and suggested an additional mechanism: an inner layer retinal posterior

pole rheological event that results in vascular endothelial dysregulation.⁴⁸ Probably, these mechanisms are not mutually exclusive and there is some overlap in the final mechanism: precapillary arterioles occlusion by altered retinal microvascular permeability.^{2–4,7}

Regarding treatment, several articles and reviews such as our own did not find corticosteroid treatment associated with a statistically significant improvement in outcome.^{1,2,5} Observation and treatment of the underlying etiology may be the most reasonable therapeutic option without risk of adverse drug effects. However, since some case reports showed hastened visual recovery after corticosteroids use,^{2,49} further information is needed to determine if corticosteroids can or cannot change the natural history of a patient with Purtscher's retinopathy. Visual improvement in those cases has been attributed to the ability of corticosteroids to stabilize damaged neuronal membrane and microvascular channels, and to inhibit granulocyte aggregation related to complement activation.^{7,50}

Eventually, a trial (preferably masked) with corticosteroids in PuR could be considered to end controversies about the need of this treatment. Preferably, a natural history cohort study might be the most reasonable first step. The biggest barrier to any prospective study design is the small frequency of this pathology, estimated as 0.24 per million.² Ultimately, a National or International Study might be necessary.

Also, to estimate the real incidence and to identify asymptomatic cases of PuR (which are of relatively high frequency^{3,51}), more screening should be done in patients identified to be at risk. This study may assist in the identification of such individuals. In all cases, evaluation by an ophthalmologist is essential. Follow-up is crucial as well, and should have defined timelines (we suggest measuring VA at presentation, at 1 month, at 2 months, and at 6 months) using a standard methodology. We recommend diagnostic criteria for Purtscher's retinopathy (similar to the one used by Agrawal² and adapted by us).

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

We would like to thank MSD for obtaining the full text of 9 articles, and Théa for obtaining the full text of 21 articles.

References

- 1 Purtscher O. Noch unbekannte befunde nach schadeltrauma. *Ber Dtsch Ophthalmol Ges* 1910; **36**: 294–301.
- 2 Agrawal A, McKibbin M. Purtscher's retinopathy: epidemiology, clinical features and outcome. *Br J Ophthalmol* 2007; **91**(11): 1456–1459.
- 3 Holló G. Frequency of Purtscher's retinopathy. *Br J Ophthalmol* 2008; **92**(8): 1159.
- 4 Proença Pina J, Ssi-Yan-Kai K, de Monchy I, Charpentier B, Offret H, Labetoulle M. Purtscher-like retinopathy: case report and review of the literature. *J Fr Ophthalmol* 2008; **31**(6): 609.
- 5 Kincaid MC, Green WR, Knox DL, Mohler C. A clinicopathological case report of retinopathy of pancreatitis. *Br J Ophthalmol* 1992; **66**(4): 219–226.
- 6 Medeiros HA, Medeiros JA, Caliani LC, Silva J. Purtscher's and Purtscher-like retinopathies. *Rev Bras Ophthalmol* 2009; **68**(2): 114–119.
- 7 Agrawal A, McKibbin M. Purtscher's retinopathies: a review. *Surv Ophthalmol* 2006; **51**: 129–136.
- 8 Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions*, Version 5.0.0 26th Vol (John Wiley & Sons: Chichester (UK), 2008; 434–449).
- 9 Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. STARD group. Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. *Am J Clin Pathol* 2003; **119**(1): 18–22.
- 10 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology* 2007; **18**(6): 800–804.
- 11 Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. *Am J Ophthalmol* 1982; **94**: 91–96.
- 12 Cernea D, Răscăanu A, Bârjoveanu F, Berteanu C. Retinopathy in severe acute pancreatitis. *Oftalmologia* 2009; **53**(3): 123–129.
- 13 Karoui El, Karras A, Lebrun G, Charles P, Arlet JB, Jacquot C et al. Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor? *Arthritis Rheum* 2009; **61**(11): 1609–1613.
- 14 Krahulec B, Stefanicková J, Hlinskáková S, Hirnerová E, Kosmálová V, Hasa J et al. Purtscher-like retinopathy—a rare complication of acute pancreatitis. *Vnitr Lek* 2008; **54**(3): 276–281.
- 15 Sauer A, Nasica X, Zorn F, Petitjean P, Bader P, Speeg-Schatz C et al. Cryoglobulinemia revealed by a Purtscher-like retinopathy. *Clin Ophthalmol* 2007; **1**(4): 555–557.
- 16 Stewart MW, Brazis PW, Guier CP, Thota SH, Wilson SD. Purtscher-like retinopathy in a patient with HELLP syndrome. *Am J Ophthalmol* 2007; **143**(5): 886–887.
- 17 Okwuosa TM, Lee EW, Starosta M, Chohan S, Volkov S, Flicker M et al. Purtscher-like retinopathy in a patient with adult-onset Still's disease and concurrent thrombotic thrombocytopenic purpura. *Arthritis Rheum* 2007; **57**(1): 182–185.
- 18 Holak HM, Holak S. Prognostic factors for visual outcome in Purtscher retinopathy. *Surv Ophthalmol* 2007; **52**(1): 117–118; with author reply 118–9.
- 19 Parc C. Purtscher-like retinopathy as an initial presentation of a thrombotic microangiopathy associated with antineoplastic therapy. *Am J Hematol* 2007; **82**(6): 486–488.
- 20 Holak HM, Holak NH, Schenk C, Olinger A, Holak SA. [Correlation of retinal thickness with the extent of

- Purtscher's retinopathy]. *Ophthalmologe* 2006; **103**(9): 798–805.
- 21 López-Tizón E, Reinoso-Montalvo C, Mencía-Gutiérrez E, Gutiérrez-Díaz E. Acute pancreatitis presenting as sudden blindness. *Arch Soc Esp Oftalmol* 2006; **81**(3): 161–163.
 - 22 Nayak H, Harun S, Palimar P. Purtscher's retinopathy after fracture dislocation of shoulder joint. *Emerg Med J* 2005; **22**(11): 831–832.
 - 23 Lai WW, Chen AC, Sharma MC, Lam DS, Pulido JS. Purtscher-like retinopathy associated with acute renal allograft rejection. *Retina* 2005; **25**(1): 85–87.
 - 24 Ong T, Nolan W, Jagger J. Purtscher-like retinopathy as an initial presentation of thrombotic thrombocytopenic purpura: a case report. *Eye (Lond)* 2005; **19**(3): 359–361.
 - 25 Castillo BV Jr, Khan AM, Gieser R, Shownkeen H. Purtscher-like retinopathy and Horner's syndrome following coil embolization of an intracavernous carotid artery aneurysm. *Graefes Arch Clin Exp Ophthalmol* 2005; **243**(1): 60–62.
 - 26 Kocak N, Kaynak S, Kaynak T, Oner HF, Cingil G. Unilateral Purtscher-like retinopathy after weight-lifting. *Eur J Ophthalmol* 2003; **13**(4): 395–397.
 - 27 Roncone DP. Purtscher's retinopathy. *Optometry* 2002; **73**(3): 166–172.
 - 28 Haq F, Vajaranant TS, Szlyk JP, Pulido JS. Sequential multifocal electroretinogram findings in a case of Purtscher-like retinopathy. *Am J Ophthalmol* 2002; **134**(1): 125–128.
 - 29 Lim BA, Ang CL. Purtscher-like retinopathy after retrobulbar injection. *Ophthalmic Surg Lasers* 2001; **32**(6): 477–478.
 - 30 Myers JP, Di Bisceglie AM, Mann ES. Cryoglobulinemia associated with Purtscher-like retinopathy. *Am J Ophthalmol* 2001; **131**(6): 802–804.
 - 31 Zwolińska D, Medyńska A, Galar A, Turno A. Purtscher-like retinopathy in nephrotic syndrome associated with mild chronic renal failure. *Pediatr Nephrol* 2000; **15**(1-2): 82–84.
 - 32 Fumex L, Boizard Y, Burillon C, Denis P. Purtscher retinopathy in acute alcoholic pancreatitis. A case report. *J Fr Ophthalmol* 2004; **27**(8): 927–931.
 - 33 Voinea L, Totir M, Badarau A, Stana D, Pavel L, Panca A et al. Purtscher retinopathy-case report. *Oftalmologia* 2009; **53**(2): 44–47.
 - 34 Holak H, Holak N, Huzarska M, Holak S. [Pathogenesis of Purtscher's retinopathy and Purtscher-like retinopathy]. *Klin Oczna* 2007; **109**(1–3): 38–45.
 - 35 Schenk C, Holak H, Holak N, Olinger A. [Purtscher's syndrome. An example of a rare occurrence of ocular complication after thoracic compression trauma]. *Unfallchirurg* 2005; **108**(2): 167–169.
 - 36 Behrens-Baumann W, Scheurer G. [Purtscher disease. Range of variation of clinical manifestations in 11 patients and pathogenetic considerations]. *Klin Monbl Augenheilkd* 1991; **198**(2): 99–107.
 - 37 Fellingner C, Kunz R. [Unilateral Purtscher traumatic angiopathy]. *Klin Monbl Augenheilkd* 1986; **188**(6): 599–600.
 - 38 Zehetbauer G. [Pathogenesis of the traumatic retinal angiopathy "Purtscher"]. *Klin Monbl Augenheilkd* 1973; **163**(2): 198–200.
 - 39 Tenner A, Pape R, Genée E. [Fluorescence angiography and ophthalmodynamography in the late stage of Morbus Purtscher]. *Klin Monbl Augenheilkd* 1972; **160**(1): 109–113.
 - 40 Schmidt JG. [Traumatic retinal angiopathy (Purtscher) and fat embolism]. *Klin Monbl Augenheilkd* 1968; **152**(5): 672–679.
 - 41 –Justice J Jr, Lehmann RP. Cilioretinal arteries. *Arch Ophthalmol* 1976; **94**(8): 1355–1358.
 - 42 Chuang EL, Miller FS, Kalina RE. Retinal lesions following long bone fractures. *Ophthalmology* 1985; **92**: 370–374.
 - 43 Carrera CR, Pierre LM, Medina FM, Pierre P. Purtscher-like retinopathy associated with acute pancreatitis. *Sao Paulo Med J* 2005; **123**(6): 289–291.
 - 44 Sellami D, Ben Zina Z, Jelliti B, Abid D, Feki J, Chaâbouni M. Purtscher-like retinopathy in systemic lupus erythematosus. Two cases. *J Fr Ophthalmol* 2002; **25**(1): 52–55.
 - 45 Craddock PR, Hammerschmidt D, White JG, Dalmosso AP, Jacob HS. Complement (C5-a)-induced granulocyte aggregation in vitro. *J Clin Invest* 1977; **60**(1): 260–264.
 - 46 Marr WG, Marr EG. Some observations on Purtscher's disease. *Am J Ophthalmol* 1962; **54**: 693.
 - 47 Nautiyal A, Amesua G, Jameson A, Gradowski JF, Hong F, Doft B. Sudden loss of vision: Purtscher retinopathy in multiple myeloma. *Can Med Assoc J* 2009; **181**(12): E277.
 - 48 Harrison TJ, Abbasi CO, Khraishi TA. Purtscher retinopathy: an alternative etiology supported by computer fluid dynamic simulations. *Invest Ophthalmol Vis Sci* 2011; **52**(11): 8102–8107.
 - 49 Wang AG, Yen MY, Liu JH. Pathogenesis and neuroprotective treatment in Purtscher's retinopathy. *Jpn J Ophthalmol* 1988; **42**–45.
 - 50 Hammerschmidt DE, White JG, Craddock PR, Jacob HS. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. *J Clin Invest* 1979; **63**(4): 798–803.
 - 51 Bhan K, Ashiq A, Aralikatti A, Menon KV, McKibbin M. The incidence of Purtscher retinopathy in acute pancreatitis. *Br J Ophthalmol* 2008; **92**(1): 151–153.
 - 52 Blodi BA, Williams CA. Purtscher-like retinopathy after uncomplicated administration of retrobulbar anesthesia. *Am J Ophthalmol* 1997; **124**(5): 702–703.
 - 53 Alasil T, Tokuhara K, Bowes LD, Fan J. Purtscher-Like Retinopathy: Optical Coherence Tomography and Visual Field Findings. *Ophthalmic Surg Lasers Imaging* 2010; **9**: 1–4.
 - 54 Miguel A, Lopes N, Neves M, Andres R, Henriques F, Roque-Loureiro A. Purtscher's retinopathy with contralateral traumatic optic neuropathy – case report. *Oftalmologia* 2010; **34**(2): 399–405.
 - 55 Tajunisah I, Patel DK, Subrayan V. Purtscher retinopathy as an initial presentation of thrombotic thrombocytopenic purpura. *J Thromb Thrombolysis* 2010; **30**(1): 112–113.
 - 56 Sturm V, Menke MN, Landau K, Laube GF, Neuhaus TJ. Ocular involvement in paediatric haemolytic uraemic syndrome. *Acta Ophthalmol* 2010; **88**(7): 804–807.
 - 57 Bécheur H, Machevin L, Mostefa-Kara N, Zahedi R. Purtscher' ischemic retinopathy consecutive to an acute pancreatitis. *Gastroenterol Clin Biol* 2001; **25**(10): 922–924.
 - 58 Bui SK, O'Brien JM, Cunningham ET Jr. Purtscher retinopathy following drug-induced pancreatitis in an HIV-positive patient. *Retina* 2001; **21**(5): 542–545.
 - 59 Patel MR, Bains AK, O'Hara JP, Kallab AM, Marcus DM. Purtscher retinopathy as the initial sign of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. *Arch Ophthalmol* 2001; **119**(9): 1388–1389.
 - 60 Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. *Arch Ophthalmol* 2000; **118**(5): 726–727.
 - 61 Tabandeh H, Rosenfeld PJ, Alexandrakis G, Kronish JP, Chaudhry NA. Purtscher-like retinopathy associated with

- pancreatic adenocarcinoma. *Am J Ophthalmol* 1999; **128**(5): 650–652.
- 62 Power MH, Regillo MC, Custis PH. Thrombotic thrombocytopenic purpura associated with Purtscher retinopathy. *Arch Ophthalmol* 1997; **115**(1): 128–129.
- 63 Atabay C, Kansu T, Nurlu G. Late visual recovery after intravenous methylprednisolone treatment of Purtscher's retinopathy. *Ann Ophthalmol* 1993; **25**(9): 330–333.
- 64 Schipper I. [Valsalva's maneuver: not always benign]. *Klin Monbl Augenheilkd* 1991; **198**(5): 457–459.
- 65 Teichmann KD, Gronemeyer U. Unilateral morbus Purtscher with poor visual outcome. *Ann Ophthalmol* 1981; **13**(11): 1295–1299.
- 66 Baarsma GS, van Balen TM. Purtscher's disease. *Doc Ophthalmol* 1977; **44**(1): 95–104.
- 67 Tomasi LG, Rosman NP. Purtscher retinopathy in the battered child syndrome. *Am J Dis Child* 1975; **129**(11): 1335–1337.